The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2009Parkinson's Disease, Ashkenazi Jews and LRRK2: a consortium proposal
Objective/Rationale:
Mutations in the LRRK2 gene are the most common genetic cause of classic or typical Parkinson’s disease (PD). One mutation, G2019S, is especially frequent in Jewish (about 14%)... -
MJFF Research Grant, 2009Clinicogenetic Studies of LRRK2 G2019S in Tunisia
Objective/Rationale:
Parkinson’s disease (PD) is a prevalent, heterogeneous disorder with a complex, multifactorial etiology. In Tunisia, North Africa, the burden of genetically-defined LRRK2 G2019S... -
MJFF Research Grant, 2009Biomarker Battery Assessment in LRRK2
Objective/Rationale:
Parkinson disease (PD) has a pre-clinical phase characterized by death of dopamine neurons in the substantia nigra and other brain regions, which precedes the development of... -
MJFF Research Grant, 2009DAT Imaging in Ashkenazi Jews (AJ) LRRK2 Gene Carriers - a consortium proposal
Objective/Rationale:
While most PD is not associated with a specific genetic cause, in some ethnic populations such as Ashkenazi Jews there is a high prevalence of a genetic cause for PD affecting a... -
Rapid Response Innovation Awards, 2009Accurate Drosophila Genetic Models of LRRK2-based Parkinson's Disease
Objective/Rationale:
The most common hereditary form of Parkinson’s Disease (PD) results from mutations of the LRRK2 gene in humans. The model genetic organism, Drosophila melanogaster (fruit fly)... -
Rapid Response Innovation Awards, 2009Uncovering Factors that Prevent Dopaminergic Neuronal Degeneration in a Novel C. elegans Model for Parkinson's Disease using a High-throughput Forward Genetics Approach
Objective/Rationale:
Our inability to slow down the progression of Parkinson’s disease (PD) reflects our incomplete knowledge of the molecular mechanisms that cause the selective death of dopaminergic...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.